GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (OSTO:IBT B) » Definitions » ROE % Adjusted to Book Value

Infant Bacterial Therapeutics AB (OSTO:IBT B) ROE % Adjusted to Book Value : -26.82% (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB ROE % Adjusted to Book Value?

Infant Bacterial Therapeutics AB's ROE % for the quarter that ended in Sep. 2024 was -59.27%. Infant Bacterial Therapeutics AB's PB Ratio for the quarter that ended in Sep. 2024 was 2.21. Infant Bacterial Therapeutics AB's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -26.82%.


Infant Bacterial Therapeutics AB ROE % Adjusted to Book Value Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB ROE % Adjusted to Book Value Chart

Infant Bacterial Therapeutics AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.76 -5.30 -5.67 -10.66 -9.74

Infant Bacterial Therapeutics AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.96 -12.65 -9.82 -12.03 -26.82

Competitive Comparison of Infant Bacterial Therapeutics AB's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Infant Bacterial Therapeutics AB's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's ROE % Adjusted to Book Value falls into.



Infant Bacterial Therapeutics AB ROE % Adjusted to Book Value Calculation

Infant Bacterial Therapeutics AB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-38.65% / 3.97
=-9.74%

Infant Bacterial Therapeutics AB's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-59.27% / 2.21
=-26.82%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Infant Bacterial Therapeutics AB ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Infant Bacterial Therapeutics AB Business Description

Traded in Other Exchanges
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines